{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:39:57Z","timestamp":1761093597276,"version":"build-2065373602"},"reference-count":12,"publisher":"Wiley","issue":"6P2","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":2045,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:p>The availability of new antifungal agents with novel mechanisms of action and improved tolerability has widened the possibilities for combination therapy for difficult\u2010to\u2010treat opportunistic mycoses. However, empiricism largely governs this therapy, especially in patients with invasive mould infections for whom there is a dire need to improve outcomes. Because of difficulties associated with the design and conduct of clinical trials of combination therapy for opportunistic mycoses, most studies are still performed in the laboratory or in animal models. Methods to assess combined antifungal effects in vitro and in animals are poorly standardized, and little evidence suggests that the data generated from these studies are relevant to treating patients. Even without solid evidence to support routine combination therapy, certain principles can guide its use in select patients.<\/jats:p>","DOI":"10.1592\/phco.26.6part2.61s","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:13:57Z","timestamp":1148303637000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Decision Making in Antifungal Monotherapy versus Combination Therapy"],"prefix":"10.1002","volume":"26","author":[{"given":"Russell E.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05007.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/375420"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.693-715.2004"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707033370103"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16301-0"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/374850"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11479"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/423380"},{"key":"e_1_2_1_10_2","unstructured":"SinghN LimayeA SafdarN et al.Safety and tolerability of voriconazole plus caspofungin in solid organ transplant recipients with invasive aspergillosis. Presented at the 45th interscience conference on antimicrobial agents and chemotherapy Washington DC December 1619 2005."},{"key":"e_1_2_1_11_2","unstructured":"ChamilosG LunaM LewisRE et al.Invasive fungal infections in patients with hematological malignancies at a tertiary cancer center: a 15\u2010year (1989\u20132003) autopsy study. Presented at the 15th European congress of clinical microbiology and infectious diseases Copenhagen Denmark April 25 2005."},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/428780"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.830-832.2005"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.26.6part2.61S","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.26.6part2.61S","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:09:32Z","timestamp":1761048572000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.26.6part2.61S"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":12,"journal-issue":{"issue":"6P2","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1592\/phco.26.6part2.61S"],"URL":"https:\/\/doi.org\/10.1592\/phco.26.6part2.61s","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}